Browse by author
Lookup NU author(s): Professor Alan Calvert
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Carboplatin haematological toxicities are clearly related to AUC. It seems likely that therapeutic efficacy is also related to AUC, although the maturation of clinical trials is necessary to establish this point. Using AUG-based dosing compensates for variations in renal function between and within individual patients. Since this variability is considerable, AUG-based dosing is a desirable practice. However; it does not allow for other factors such as previous chemotherapy, previous radiotherapy or performance status. Thus it does not remove the Requirement for clinical judgements when managing a patient with cancer; it simply helps to remove one of the subjective elements of such judgements.
Author(s): Calvert, A. H.
Publication type: Article
Publication status: Published
Journal: Anticancer Research
Year: 1994
Volume: 14
Issue: 6A
Pages: 2273-2277
Print publication date: 01/11/1994
ISSN (print): 0250-7005
ISSN (electronic): 1791-7530
Notes: Originally presented at the 5th Conference on Oncological Clinical Pharmacology, 08/10-11-1994, Reims, France.
